Company profile: Revolution Medicines
1.1 - Company Overview
Company description
- Provider of RAS(ON) inhibitors for RAS-addicted cancers, including RMC-6236 (multi-selective), RMC-6291 (G12C-selective), and RMC-9805 (G12D-selective); and a tri-complex inhibitor platform enabling creation of inhibitors that target the active state of RAS proteins.
Products and services
- Tri-complex inhibitor platform: Active-state-targeting platform architects inhibitors that target RAS(ON) proteins, enabling a novel approach to treating RAS-addicted cancers
- RMC-6236: Multi-selective RAS(ON) inhibitor delivers targeted blockade for treating RAS-addicted cancers by engaging the active state
- RMC-6291: G12C-selective RAS(ON) inhibitor produces mutation-specific targeting for RAS-addicted cancers, focusing precisely on the G12C variant
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Revolution Medicines
Theraclone Sciences
HQ: United States
Website
- Description: Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclone Sciences company profile →
Scorpion Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision oncology therapeutics, developing small-molecule inhibitors targeting the H1047X-mutant PI3Kα in solid tumors (STX-H1047-PI3Kα) and exon 20 insertion mutations in EGFR driving non-small cell lung cancer (STX-EGFR-EXON20).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scorpion Therapeutics company profile →
Epigenomics
HQ: Germany
Website
- Description: Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epigenomics company profile →
Endocare
HQ: United States
Website
- Description: Provider of medical devices and related consumables for cryoablation, developing, manufacturing, and distributing these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endocare company profile →
Elicio Therapeutics
HQ: United States
Website
- Description: Provider of lymph node-targeted vaccines designed to directly target the lymph nodes to treat aggressive cancers and infectious diseases; a pharmaceutical research company developing immuno-tumor vaccines to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elicio Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Revolution Medicines
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Revolution Medicines
2.2 - Growth funds investing in similar companies to Revolution Medicines
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Revolution Medicines
4.2 - Public trading comparable groups for Revolution Medicines
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →